ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Pulmonary Involvement"

  • Abstract Number: 2727 • 2014 ACR/ARHP Annual Meeting

    T Cells Trigger Interstitial Pneumonia in Polymyositis

    Akira Takeda1,2, Yasutsugu Fukushima3, Takaji Matsutani4, Yoichiro Haji1, Chisun Min1, Ryo Rokutanda1, Yasuhiro Suyama1, Mitsumasa Kishimoto5, Ken-ichi Yamaguchi1 and Masato Okada6, 1Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 2Division of Clinical Immunology & Rheumatology, International University of Health and Welfare Hospital, Nasu-shiobara, Japan, 3Department of Pulmonary Medicine and Clinical Immunology, Dokkyo University School of Medicine, Mibu, Japan, 4Laboratory of Immune Regulation, Wakayama Medical University, Ibaraki, Japan, 5St. Luke's International Hospital, Tokyo, Japan, 6Immuno-Rheumatology Center, St. Luke's International Hospital, tokyo, Japan

    Background/Purpose: The lung is frequently affected in connective tissue diseases (CTDs). Polymyositis (PM) is a major CTD characterized by idiopathic inflammatory lesions of muscle and…
  • Abstract Number: 2701 • 2014 ACR/ARHP Annual Meeting

    Relevance of the 6-Minute Walking Test in Assessing the Severity and Outcome of Pulmonary Arterial Hypertension Associated with Systemic Sclerosis, without Extensive Interstitial Lung Disease

    Sébastien Sanges1,2,3, David Launay1,2,3, Rennie L. Rhee4, Olivier Sitbon5,6,7, Eric Hachulla2,3,8, Luc Mouthon9, Loïc Guillevin9, Laurence Rottat5,6,7, Pierre Clerson10, Jean-Francois Cordier11, Steven M. Kawut12, Gérald Simonneau5,6,7 and Marc Humbert5,6,7, 1Université Lille Nord de France, Faculté de Médecine Henri Warembourg, Lille, Lille, France, 2EA 2686, Lille, Lille, France, 3Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, 4Rheumatology, University of Pennsylvania, Philadelphia, PA, 5Université Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, France, 6Service de Pneumologie, DHU Thorax Innovation, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France, 7INSERM U999, Centre Chirurgical Marie-Lannelongue, LabEx LERMIT, Le Plessis-Robinson, Le Plessis-Robinson, France, 8Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, 9National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, 10Orgametrie, Roubaix, France, 11Division of Pneumology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon 1, Lyon, France, 12Pulmonary and Critical Care, University of Pennsylvania, Philadelphia, PA

    Background/Purpose In pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc), no study has yet evaluated the correlation between the 6-minute walking test (6MWT) distance…
  • Abstract Number: 2698 • 2014 ACR/ARHP Annual Meeting

    Survival in Systemic Sclerosis-Pulmonary Arterial Hypertension By Serum Autoantibody Status

    Monique Hinchcliff1,2, Saira Khanna3, Jungwha Lee4,5, Orit Almagor6, Rowland W. Chang2,7, Virginia D. Steen8 and Lorinda Chung9, 1Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 4Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 5Preventive Medicine, Northwestern University Medical School, Chicago, IL, 6Northwestern University, Chicago, IL, 7Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 8Department of Rheumatology, Georgetown University Medical Center, Washington, DC, 9Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA

    Background/Purpose: Previous studies have shown that anticentromere (AC) and isolated nucleolar (NUC) antibodies are the most common autoantibodies in patients with systemic sclerosis (SSc) and…
  • Abstract Number: 2169 • 2014 ACR/ARHP Annual Meeting

    Targeting ITGAM+ Cells Successfully Treats a Model of Anti-RNP-Associated Pulmonary Hypertension

    Vineet Gupta1, Yunjuan Zang2, Karen Young3, Jian Huang3, Irina Fernandez2 and Eric L. Greidinger2,4, 1Drug Discovery Center, Rush University Medical Center, Chicago, IL, 2Rheumatology, University of Miami, Miami, FL, 3Pediatrics, University of Miami, Miami, FL, 4Miami VAMC, Miami, FL

    Background/Purpose: Aggressive immunotherapy has shown modest effectiveness for pulmonary hypertension in anti-RNP Autoimmunity, but with high morbidity.  We studied the ability of an ITGAM-targeted therapy…
  • Abstract Number: 1931 • 2014 ACR/ARHP Annual Meeting

    Mycophenolate Mofetil (MMF) Use in Scleroderma Patients with Pulmonary  Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort

    Lesley Ann Saketkoo1, Matthew R. Lammi2, Aryeh Fischer3, Jerry A. Molitor4 and Virginia D. Steen5, 1Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, 2Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, 3Rheumatology / ILD Program, National Jewish Health, Denver, CO, 4Rheumatology, University of Minnesota, Minneapolis, MN, 5Department of Rheumatology, Georgetown University Medical Center, Washington, DC

    Background/Purpose: Systemic sclerosis (SSc) related pulmonary hypertension (PH) carries a high mortality and patients with SSc-PH related to restrictive lung disease having an even worse…
  • Abstract Number: 2072 • 2013 ACR/ARHP Annual Meeting

    Decreased Number Of Circulating NK Cells and Dramatic Lack Of IFN-Gamma Production In Patients With Antisynthetase Syndrome

    Baptiste Hervier1,2, Yves Allenbach3,4, Fleur Cohen-Aubart5, Micheline Pha6, Lenaig Mescam-Mancini7, David Saadoun8, Alexis Mathian5,6, Olivier Benveniste9,10 and Vincent Vieillard1, 1INSERM UMR-S 1135, UPMC, Paris, France, 2Internal Medicine & Clinical Immunology Dpt, Pitié-Salpêtrière Hospital, APHP, Paris, France, 3Internal Medicine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France, 4INSERM UMR974, UPMC, Paris, France, 5Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, 6INSERM UMR-S 945, UPMC, Paris, France, 7Pathology Dpt, University hospital, Grenoble, France, 8DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, 9UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, 10Internal Medecine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France

    Background/Purpose: Antisynthetase syndrome (ASS) is a rare autoimmune myositis associated with interstitial lung disease (ILD) and characterized by specific anti-tRNA-synthetase autoantibodies (ARS). To date, the…
  • Abstract Number: 2052 • 2013 ACR/ARHP Annual Meeting

    The Prevalence and Pattern Of Self Reported Joint Symptoms In Cystic Fibrosis

    Carl Orr1, Cormac McCarthy1, Johan Meurling1, Paul G. O'Connell2, Cedric Gunaratnam1,3 and Noel G McElvaney1, 1Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland, 2Rheumatology, Beaumont Hospital, Dublin, Ireland, 3Department of Respiratory Medicine, Beaumont Hospital, Dublin, Ireland

    Background/Purpose: Arthritis in cystic fibrosis (CF) can be very incapacitating, and it is mainly of three types: CF arthritis, hypertrophic osteoarthropathy, and arthritis due to…
  • Abstract Number: 2012 • 2013 ACR/ARHP Annual Meeting

    Gender Influences On Organ Manifestations In a New Orleans Sarcoidosis Population

    Adam Janot1, McCall Walker2, Mary Yu1, Harmanjot K. Grewal3, Matthew R. Lammi4,5 and Lesley Ann Saketkoo6,7, 1Internal Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, 2LSUHSC School of Medicine, New Orleans, LA, 3Rheumatology, Lousiana State University Health Sciences Center, New Orleans, LA, 4Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, 5Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, 6LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, 7Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA

    Background/Purpose: Sarcoidosis is a multi-organ disease in which pulmonary manifestations predominate. The skin, eyes, heart, gastrointestinal tract (GI), reticuloendothelial, renal and nervous systems are also…
  • Abstract Number: 1936 • 2013 ACR/ARHP Annual Meeting

    Quality Of Care In Patients At Risk For Pulmonary Involvement:  Assessment Of Pulmonary Screening In Systemic Sclerosis and Myositis Patients In a General Rheumatology Clinic

    Michael G. Indelicato1, Janet E. Lewis2, Vincent J. Giuliano3 and Donald L. Kimpel4, 1Rheumatology, University of Virginia, Charlottesville, VA, 2Rheumatology, University of Virginia School of Medicine, Charlottesville, VA, 3University of Virginia, Charlottesville, VA, 4Rheumatology and Immunology, University of Virginia School of Medicine, Charlottesville, VA

    Background/Purpose: As a quality assessment tool to evaluate patient care in a general Rheumatology Clinic, we determined the frequency of screening for pulmonary hypertension and…
  • Abstract Number: 1814 • 2013 ACR/ARHP Annual Meeting

    The Risk Of Pulmonary Embolism and Deep Venous Thrombosis In Systemic Sclerosis: A Population-Based Cohort Study

    J. Antonio Avina-Zubieta1, Iman Hemmati2, Eric C. Sayre3, Kamran Shojania3,4 and Hyon Choi3,5,6, 1Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, 2Deparment of Medicine and Rheumatology, University of British Columbia, Vancouver, BC, Canada, 3Arthritis Research Centre of Canada, Richmond, BC, Canada, 4Rheumatology, University of British Columbia, Vancouver, BC, Canada, 5Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 6Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Data on the risk of pulmonary embolism (PE) and deep venous thrombosis (DVT) in patients with systemic sclerosis (SSc) is lacking. To fill this…
  • Abstract Number: 1775 • 2013 ACR/ARHP Annual Meeting

    Use Of “Computer-Aided Lung Informatics For Pathology Evaluation and Rating” Software In High-Resolution Computed Tomography In Patients With Idiopathic Inflammatory Myopathy and Interstitial Lung Disease

    Katelynn Wilton1, Brian Bartholmai2, Sanjay Kalra3, Cynthia S. Crowson4, Helen Khun4 and Floranne C. Ernste5, 1Mayo Clinic College of Medicine, Rochester, MN, 2Thoracic Radiology, Mayo Clinic, Rochester, MN, 3Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, 4Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 5Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN

    Background/Purpose: The idiopathic inflammatory myopathies (IIM) are associated with interstitial lung disease (ILD), characterized by parenchymal abnormalities on high-resolution computed tomography (HRCT). We determined the…
  • Abstract Number: 1746 • 2013 ACR/ARHP Annual Meeting

    Pericardial Effusions Are Not a Poor Prognostic Factor In Systemic Sclerosis Patients With Pulmonary Hypertension

    Elana J. Bernstein1, Jessica K. Gordon2, Wei-Ti Huang3 and Virginia D. Steen4, 1Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Biostatistics, Hospital for Special Surgery, New York, NY, 4Department of Rheumatology, Georgetown University Medical Center, Washington, DC

    Background/Purpose: Pulmonary hypertension (PH) (defined as a mean pulmonary arterial pressure ≥ 25 mmHg on right heart catheterization) is a leading cause of death in…
  • Abstract Number: 738 • 2013 ACR/ARHP Annual Meeting

    Pulmonary Fibrosis In ANCA-Associated Vasculitis

    Cloé Comarmond1, Bruno Crestani2, Abdellatif Tazi3, Baptiste Hervier4, Sylvain Adam-Marchand5, Hilario Nunes6, Fleur Cohen-Aubart7, Marie Wislez8, Jacques Cadranel8, Bruno Housset9, Célia Lloret-Linares10, Pascal Sève11, Christian Pagnoux12, Sébastien Abad13, Juliette Camuset14, Boris Bienvenu15, Michael Duruisseaux16, Eric Hachulla17, Jean-Benoît Arlet18, Mohamed Hamidou19, Alfred Mahr20, Anne-Laure Brun21, Philippe Grenier21, Patrice Cacoub22 and David Saadoun23, 1Internal Medicine and Clinical Imunology, Referal Center for Autoimmune diseases, Internal Medicine and Clinical Imunology, Hôpital Pitié Salpétrière, Paris, France, 2Pneumology A, Hôpital Bichat, Paris, France, 3Hôpital Saint-Louis, Paris, France, 4Internal Medicine & Clinical Immunology Dpt, Pitié-Salpêtrière Hospital, APHP, Paris, France, 5Pneumology, Centre Hospitalier Universitaire de Tours, Tours, France, 6Department of Pneumology, Avicenne Hospital (AP-HP), Bobigny, France, 7Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, 8Pneumology, Hôpital Tenon, Paris, France, 9Pneumology, Centre Hospitalier Intercommunal de Créteil, Créteil, France, 10Médecine Interne A, Hôpital Lariboisière, Paris, France, 11Internal medicine, CHU Lyon, Lyon, France, 12Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, 13Internal Medicine, Avicenne Hospital, Bobigny, France, 14Pneumology, Centre Hospitalier Victor Dupouy, Argenteuil, France, 15Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France, 16Pneumology, CHU de Grenoble, Grenoble, France, 17Internal Medicine, Lille CEDEX, France, 18Internal Medicine, HEGP, Paris, France, 19Internal Medicine Department, Nantes University Hospital, Nantes, France, 20Department of Internal Medicine, Hospital Saint-Louis, Paris, France, 21Radiology, Hôpital Pitié-Salpêtrière, Paris, France, 22Médecine Interne 2, Hopital Pitié-Salpétrière, Paris, France, 23Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France

    Background/Purpose: The association of pulmonary fibrosis (PF) with anti neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), especially microscopic polyangiitis (MPA), is rare but related to poor…
  • Abstract Number: 2707 • 2013 ACR/ARHP Annual Meeting

    Downregulation Of KLF5 and Fli1 Cooperatively Contribute To Distinct Manifestations Of Systemic Sclerosis In Vitro and In Vivo

    Shinji Noda1, Yoshihide Asano1, Katsuhito Fujiu2, Ichiro Manabe2, Ryozo Nagai2, Kaname Akamata1, Takashi Taniguchi1, Takehiro Takahashi1, Yohei Ichimura1, Tetsuo Toyama1, Daisuke Tsuruta3, Maria Trojanowska4 and Shinichi Sato1, 1Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, 2Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan, 3Dermatology, Osaka City University Graduate School of Medicine, Osaka, Japan, 4Arthritis Center, Boston University, Boston, MA

    Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by initial vascular injuries and resultant fibrosis of skin and certain internal organs. Although the…
  • Abstract Number: 695 • 2013 ACR/ARHP Annual Meeting

    Combined Pulmonary Fibrosis and Emphysema (CPFE) In Systemic Sclerosis

    Nicolas Champtiaux1, Vincent Cottin2, Eric Hachulla3, Dominique Valeyre4, Hilario Nunes5, David Launay6, Alice Berezne7, Bruno Crestani8, Loic Guillevin9, Jean-Francois Cordier2 and Luc Mouthon10, 1Service de Médecine Interne, hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 2Division of Pneumology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon 1, Lyon, France, 3Internal Medicine, Lille CEDEX, France, 4Department of Pneumology, Avicenne hospital (APHP), Bobigny, France, 5Department of Pneumology, Avicenne Hospital (AP-HP), Bobigny, France, 6Internal Medicine, Claude Huriez University Hospital, Lille, France, 7Paris Descartes University, Internal Medicine department, Cochin Hospital, Paris, France, 8Pneumology A, Hôpital Bichat, Paris, France, 9Internal Medicine, Cochin University Hospital, Paris, France, 10Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France

    Combined pulmonary fibrosis and emphysema (CPFE) in systemic sclerosis Background/Purpose: Combined pulmonary fibrosis and emphysema (CPFE) is a recently defined syndrome, in which centrilobular and/or…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology